Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Allergic Reaction to Singulair News?

The FDA issued a warning yesterday that patients taking Merck's (NYSE: MRK  ) Singulair have reported depression and even suicidal thoughts. There's no evidence that the drug itself is causing depression or suicide, but because suicide is so serious, the FDA felt compelled to tell the public.

I don't believe there's any reason for investors to become despondent over the news, though. It's worth noting that the warning wasn't based in a placebo-controlled trial showing that there was a higher incidence of depression among patients taking Singulair. Instead, the notice was issued because a handful of suicides among patients taking Singulair have been reported to the FDA.

Singulair's label already indicates that there have been postmarketing reports of suicidal thinking, but Merck has agreed to be more vigilant about pointing out the findings to doctors as well as evaluate safety data from clinical trials for evidence of suicidal thoughts.

The FDA is also reviewing postmarketing reports from AstraZeneca's (NYSE: AZN  ) Accolate, as well as from Zyflo, which is marketed by Critical Therapeutics (Nasdaq: CRTX  ) and Dey, a new subsidiary of Mylan Labs (NYSE: MYL  ) . Those two drugs are in the same class as Singulair, but it's not clear whether there have been suicides reported with those drugs.

These types of reports have become more common. The FDA is increasingly vigilant about safety these days, after postmarketing side effects surfaced for Merck's Vioxx and GlaxoSmithKline's (NYSE: GSK  ) Avandia. That means investors in drug companies will need to sift through the warnings like this one -- which should have minimal effect on sales -- to find ones that may turn out to be more serious.

The side effect of reading these Foolish articles could be higher returns:

Fool contributor Brian Orelli , Ph.D., is allergic to something that blooms in late summer in Southern California, but he doesn't know what it is. He doesn't own shares of any company mentioned in this article. Glaxo is a selection of the Income Investor newsletter service. The Fool's disclosure policy is allergic to paper shredders.

Read/Post Comments (0) | Recommend This Article (0)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 609216, ~/Articles/ArticleHandler.aspx, 10/25/2016 5:26:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
MRK $61.95 Up +1.20 +1.98%
Merck and Co. CAPS Rating: ****
AZN $29.79 Down -0.29 -0.96%
AstraZeneca CAPS Rating: ****
GSK $40.32 Down -0.36 -0.88%
GlaxoSmithKline CAPS Rating: ***
MYL $38.68 Up +1.12 +2.98%
Mylan CAPS Rating: ***